TAK-041
- Generic Name
- TAK-041
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
Phase 2
Completed
- Conditions
- AnhedoniaMajor Depressive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 93
- Registration Number
- NCT05165394
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
Phase 2
Completed
- Conditions
- Stable Schizophrenia
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 23
- Registration Number
- NCT03319953
- Locations
- 🇬🇧
Kings College London, London, United Kingdom
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Phase 1
Completed
- Conditions
- Healthy VolunteersSchizophrenia
- Interventions
- Drug: TAK-041 Placebo
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 114
- Registration Number
- NCT02748694
- Locations
- 🇺🇸
Parexel Early Phase Clinic Unit- Los Angeles, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath